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Abstract
Background: Tumorigenesis is a multi-step process which is accompanied by substantial changes in genome
organization. The development of these changes is not only a random process, but rather comprise specific DNA
regions that are prone to the reorganization process.
Results: We have analyzed previously published SNP arrays from three different cancer types (pancreatic
adenocarcinoma, breast cancer and metastatic melanoma) and from non-malignant control samples. We calculated
segmental copy number variations as well as breakpoint regions. Some of these regions were not randomly
involved in genome reorganization since we detected fifteen of them in at least 20% of all tumor samples and one
region on chromosome 9 where 43% of tumors have a breakpoint. Further, the top-15 breakpoint regions show an
association to known fragile sites. The relevance of these common breakpoint regions was further confirmed by
analyzing SNP arrays from 917 cancer cell lines.
Conclusion: Our analyses suggest that genome reorganization is common in tumorigenesis and that some
breakpoint regions can be found across all cancer types, while others exclusively occur in specific entities.
Keywords: Pancreatic ductal adenocarcinoma, Breast cancer, Melanoma, Copy number variation, Cancer genomics,
Breakpoint and genome reorganization
Background
Tumorigenesis is a stepwise process, which involves
multiple genetic, epigenetic and genomic events to
transform a normal cell into a tumor cell [1–6].Genomic
changes like copy number variations (CNVs) or segmen-
tal copy number variations (segCNVs) increase through-
out tumorigenesis [7–9] and are caused by various
mechanisms, like fork stalling during replication or non-
allelic homologous recombination [10–12].
These changes can affect the chromatin structure and
therefore the spatial localization of specific genes, the
DNA sequence like single nucleotide mutations, amplifi-
cations, deletions or translocations as well as changes of
karyotypes like aneuploidies [1, 13–16].
It is also speculated that DNA regions exist which are
prone for reorganization. Pevzner and Tesler stated in
their seminal work “that mammalian genomes are mo-
saics of fragile regions with high propensity for rear-
rangements and solid regions with low propensity for
rearrangements [17].”
Their thesis stands in contrast to the established the-
ory of the random breakage model. The latter is based
on the following two assumptions: Chromosomal seg-
ments are conserved among different species and
chromosomal rearrangements are randomly distributed
within the genome [18]. Indeed, it is well established
that chromosomal segments exist in different species
where orthologous genes are located in the same ar-
rangement. On the other hand, it is now also established
that specific DNA regions throughout the genome are
prone to breakage and reorganization [17, 19–21].
Ruiz-Herrera et al stated that “certain chromosomal re-
gions in the human genome have been repeatedly used
in the evolutionary process. As a consequence, the
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genome is a composite of fragile regions prone to
reorganization…” Well known regions exhibiting
chromosomal instability are fragile sites, which were
firstly described by Magenis et al 1970 [22, 23]. “Fragile
sites are specific loci that form gaps, constrictions, and
breaks on chromosomes exposed to partial replication
stress and are rearranged in tumors [24].” Fragile sites
can be divided in rare and common fragile sites (CFSs).
Rare fragile sites are only expressed in a few individuals.
They are associated with the expansion of micro- or
minisatellite repeats and inheritable diseases like fragile
X syndrome. CFSs are regular parts of chromosomes
and therefore found in all humans. CFSs are hotspots
for metaphase chromosomal gaps and breaks and
chromosomal rearrangements. CFS instability is an early
step in tumorigenesis and could be responsible for gen-
ome reorganization in cancer [23, 25–29].
In 2012, Standfuß et al observed the stepwise increase
in genome reorganization in a simian virus 40 (SVT/t)
transformed mouse breast cancer model. The number of
genomic changes increased from non-malignant, to hy-
perplastic and to tumor samples of mammary glands.
Moreover, distinct breakpoint regions, where genome
reorganization events take place, could be detected.
They argued that unique and common breakpoint re-
gions exist in breast cancer. However, due to the small
sample size, the final proof was missing [9].
In this study, we analyzed DNA SNP arrays from 20
healthy controls and 111 cancer samples as well as 917
cancer cell lines. We found unique and common break-
point regions in different cancer entities and more strik-
ingly, we found a breakpoint region which was common
in more than one third of all tumors and cancer cell
lines tested.
Thus, we addressed the questions, whether genome
reorganization is a random process, and whether specific
DNA regions are prone to this reorganization procedure.
Material and methods
SNP array data
We reanalyzed 131 single-nucleotide polymorphism
(SNP) microarrays, produced using the Genome-Wide
Human SNP Array 6.0 platform (https://tools.thermo-
fisher.com/content/sfs/brochures/genomewide_snp6_
datasheet.pdf ). The 111 tumor samples compromise 25
pancreatic adenocarcinomas (PDAC) from Donahue et
al [30] [GSE32688], 22 PDAC derived cell lines from
Barretina et al [31] [GSE36139], 16 metastatic melano-
mas from Marzese et al [32] [GSE44019] and 48 breast
cancer samples from [GSE26232]. The 20 non-malignant
control experiments (NMCE) compromise 15 samples
derived from B cells isolated from peripheral blood of
healthy donors from Xie et al [33] [GSE49045] and 5
samples derived from peripheral blood cells of breast
cancer patients [GSE48377]. The 15 blood samples from
healthy donors were further termed as “reference” and
the five peripheral blood cells from breast cancer pa-
tients were termed as “control”.
Further, we analyzed 917 cancer cell line samples from
the Cancer Cell Line Encyclopedia (CCLE) [31]
[GSE36139]. All samples are publicly available.
Copy-number variation
Raw SNP microarray data was processed using the Affy-
metrix Power Tools 1.15.0 (now Oncomine™ Power
Tools, Thermo Fisher Scientific) and the BRLMM-P al-
gorithm to extract the normalized SNP signal intensities.
To compare the total signal intensity distributions of all
samples, intensities of both alleles for each SNP were
added up. CNVs for each SNP was computed as
log2-ratios of each tumor sample and the reference data-
set comprising 15 blood samples from healthy donors.
The reference for each SNP was calculated as the aver-
age signal intensity of the 15 reference samples.
SegCNVs for each sample were computed with the
DNAcopy package (1.36.0) of Bioconductor (2.13) [34]
with the following parameters: alpha = 0.001, undo.splits
= “sdundo”, undo.SD = 0.5, min.width = 4. The DNAcopy
package implements the circular binary segmentation al-
gorithm introduced by Olshen et al [35]. The number of
segCNVs were counted for each experiment and set in
relation to the number of base pairs for each chromo-
some. We excluded Chromosome Y (860 SNPs) and MT
(411 SNPs) from our analyses. The heat map was gener-
ated using ggplot2 package of R. Hg19, provided by the
University of California, Santa Cruz (UCSC), was used
for human genome assembly.
Common breakpoints
The genome was divided into 30,951 bins of 100 kb size
or less, if the bin represents a chromosomal end region.
The occurrence of each breakpoint was counted in all
1048 analyzed samples to find regions of predisposed al-
terations. To enhance stringency, a breakpoint between
two segCNVs was defined as follows: 1) the log2-ratio
difference between both segments has to be greater than
0.5. 2) at least one segment has to include a minimum
of 10 and the other of 4 SNPs.
Odds ratio
To decide whether a breakpoint event (BP) is more fre-
quent in cancer samples than in the NMCE, we calcu-
lated the odds ratios.
oddsNMCE = (number of NMCE with BP)/(total num-
ber of NMCE - number of NMCE with BP).
oddsTumor = (number of tumors with BP)/(total num-
ber of tumors - number of tumors with BP).
oddsRatio = (oddsTumors)/(oddsNMCE)
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Since some of the breakpoints were not found in the
NMCE but had a high count in the tumor group odds
ratio, calculations were not trivial. In accordance with
the Cochrane Handbook for Systematic Reviews of In-
terventions we added 0.5 in those cases:
oddsNMCE = (number of NMCE with BP + 0.5)/ (total
number of NMCE + 0.5 - number of NMCE with BP +
0.5).
oddsTumor = (number of tumors with BP + 0.5)/(total




We used the chromosomal location of the 230 fragile
sites published by Mrasek et al [36] and analyzed their
occurrence within our breakpoint regions. Therefore,
the cytogenetic location was translated into the chromo-
somal location with the help of the “Ensemble Genome
Browser version GRCh37.p13.”
Results
SNP CNVs in different tumor entities
To study the changes in genome reorganization during
tumorigenesis, we analyzed previously published SNP ar-
rays from 111 cancer samples: 25 pancreatic ductal
adenocarcinoma, 22 PDAC derived cell lines, 16 meta-
static melanoma and 48 breast cancer samples. As
NMCE, we used DNA from peripheral blood samples
from healthy donors and from breast cancer patients.
We added up the signal intensities for SNP alleles and
further determined continuous SNP CNV regions for all
chromosomes using the circular binary segmentation al-
gorithm introduced by Olshen and colleagues [35]. In
order to define DNA regions with a high probability of
genomic reorganization and which were common in
multiple cancer samples, we divided the genome into
30,951 bins of 100 kb size and defined a breakpoint re-
gion as follows: at least two DNA segments have to dif-
fer in their average copy number values of more than a
log2-ratio of 0.5 and one segment has to consist of 10
SNPs instead of the minimum of four SNPs. Thus,
breakpoint regions were defined as DNA sites where
segmental copy number level shifts occur. If a break-
point is present in multiple tumor samples, we call it
common breakpoint region. This approach is illustrated
in Fig. 1.
In total, we found 19,687 regions (63.61%) where at
least one experiment had a breakpoint. However, since
most of the breakpoint regions were present in only one
or two tumor samples, we focused on genomic regions
in which at least 23 out of the 111 tumors (20%) had a
breakpoint (Fig. 2, Table 1). The heat map shows the fif-
teen 100 kb sized breakpoint regions, which appear in at
least 20% of all tumor samples. We highlighted break-
points more frequent in PDAC tumor samples with
Fig. 1 Illustration of the experimental approach for detecting common breakpoint regions. We computed SNP-CNV - green dots - for each
chromosome (a) and computed segments of similar copy-number - red segments (b). To assess regions with frequent chromosomal aberrations,
we divided each chromosome into candidate regions of 100 kb size (c). Within each 100 kb bin, we counted each beginning of a new segCNV
with difference in log2-ratio of 0.5 as a breakpoint. Breakpoint regions with counts in multiple samples (d) were considered as common
breakpoint regions and further analyzed
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Fig. 2 To illustrate the presence (blue line) of common breakpoints within different tumor samples and tumor entities, we created a heat map.
The chromosomal location is listed on the y-axis. Here, we present a heat map for all common breakpoints that appear in at least 20% of tumor
samples. Breakpoints that were mainly common to PDAC tumor samples are marked by orange rectangles and green rectangles mark
breakpoints common to breast cancer samples
Table 1 Chromosomal location, occurrence of breakpoint events (BP), odds ratio, located genes and association to fragile sites of
the top-15 breakpoint regions. Genes that are associated with cancer in literature are marked with an asterisk










1 118000001 118100001 1p12 0 23 10,68 4 MAN1A2 –
2 4900001 5000001 2p25.2 0 23 10,68 26 – FRA2M
4 88700001 88800001 4q22.1 0 24 11,26 2 IBSP*, MPEP* FRA4F
5 45900001 46000001 5p12 0 24 11,26 1 – –
5 46300001 46400001 5p11 0 26 12,47 81 – FRA5I
7 11700001 11800001 7p21.3 0 24 11,26 5 THSD7A* FRA7L
7 37600001 37700001 7p14.1 0 23 10,68 0 NECAP1P1 –
7 103400001 103500001 7q22.1 1 23 4,97 1 RELN* FRA7F
8 43400001 43500001 8p11.1 0 25 11,86 2 – FRA8I
8 43700001 43800001 8p11.1 0 32 16,46 48 – FRA8I
8 47300001 47400001 8q11.1 0 23 10,68 1 – FRA8I
9 141000001 141100001 9q34.3 1 48 14,48 321 CACNA1B* FRA9N
13 35900001 36000001 13q13.3 0 23 10,68 1 NBEA* –
13 115100001 115106996 13q34 3 40 3,19 210 – FRA13I
14 20400001 20500001 14q11.2 3 36 2,72 61 OR4K1, OR4K5, OR4K14,
OR4K15
FRA14D
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orange boxes, and regions more frequent in breast can-
cer samples with green boxes. This result indicates that
some breakpoints are more frequent in only one tumor
entity (like chromosomes 1, 2 and 13) whereas other re-
gions are present in all tumor entities (like chromo-
somes 9 and 13). The breakpoints on Chromosomes 9
and 13 had 43 and 36% of all tumors in common. Since
some breakpoints were also present in the NMCE, we
verified the relevance of a breakpoint region by deter-
mining the odds ratio for being tumor specific.
Table 1 shows the odds ratio for the breakpoints illus-
trated in Fig. 2. In all of the top-15 breakpoint regions,
we observed that on average, an odds ratio > 10 indicates
a high prevalence for these breakpoints to occur in
tumor samples. The two highest odds ratio values were
calculated for the breakpoint of chromosome 9 present
in 48 different tumor samples and one NMCE (odds ra-
tio = 14.5) and the breakpoint on chromosome 8
(43,700,001) present only in 32 different tumor samples
(odds ratio = 16.5). Twelve genes were located in eight of
the top-15 breakpoint regions, and six of these genes are
associated with cancer (CACNA1B, IBSP, MEPE, NBEA,
RELN and THSD7A) (Table 1).
Cancer cell line encyclopedia (CCLE)
To further validate, the top-15 breakpoint regions, we in-
cluded 917 cancer cell line samples in our analyses. We
summarized in Table 2 the seven 100 kb sized breakpoint
regions which appear in at least 20% of all CCLE samples
The breakpoint regions on Chromosomes 9 (141,000,001)
and 13 (115,100,001) which were present in all tumor en-
tities, also had the most breakpoints in the analyzed can-
cer cell lines. On Chromosome 9, 321 cancer cell lines
(34%) and on Chromosome 13, 210 (22%) cancer cell lines
had a breakpoint within the aforementioned regions. Five
genes were located in four of the seven breakpoint regions
and three of these genes (CACNA1B, C8orf33 and
KIAA0513) are associated with cancer (Table 2). Interest-
ingly, only very few cancer cell lines (< 0.5%) had break-
points in the seven breakpoint regions that were
associated with PDAC: e.g. the region on chromosome 7
(37,600,001) had no breakpoint in cancer cell lines and
the regions on chromosomes 5 (45,900,001), 7
(103,400,001), 8 (47,300,001) and 13 (35,900,001) had only
one breakpoint in cancer cell lines (Table 1). The breast
cancer associated breakpoint region on chromosome 2 is
also only shared by 2.8% of cancer cell lines.
The presented results indicate that we created a set of
common breakpoint regions with the help of PDAC,
melanoma metastasis and breast cancer samples that
were more highly associated with single cancer entities,
whereas other breakpoint regions can be found in a var-
iety of tumors.
Fragile site
Since fragile sites are well known regions exhibiting
chromosome instability, we compared the chromosomal
locations of the common breakpoint regions we found
with data from chromosomal fragile sites [36]. Eleven
thousand three hundred sixty out of the 19,687 break-
point regions contained a fragile site (58%).
Since an odds ratio less than one indicates a higher
likelihood of a breakpoint region to occur in NMCE,
and an odds ratio above one indicates higher odds for
occurring in tumor samples, we determined the percent-
age of a fragile site to occur in relation to the odds ratio.
Out of the 19,687 breakpoint regions, 13,063 had an
odds ratio of less than one and 6624 above one. A region
with an odds ratio < 1 occurred in 57% (7471 out of
13,063) associated with fragile sites and a region with an
odds ratio > 1 occurred in 59% (3889 out of 6624) associ-
ated with fragile sites. Thus, we could not determine a
crucial difference in the association to fragile sites in the
more tumor linked breakpoint regions.
However, 11 of the top-15 breakpoint regions (73%) were
associated with fragile sites and 6 of the 7 CCLE related
breakpoint region (86%), indicating a strong association of
the top-ranked breakpoint regions to known fragile sites.
Targeted investigation
Further, we evaluated important regions known for
genome reorganization from literature (e.g. loss-of
Table 2 Chromosomal location, occurrence of breakpoint events (BP), odds ratio, located genes and association to fragile sites of
the top-ranked CCLE breakpoint regions. Genes that are associated with cancer in literature are marked with an asterisk.
Interestingly, the breakpoint region in chromosome 2 is close to the cancer associated SDC1 gene by about 558 bases
Chr Start End Cytoband BP in NMCE (20) BP in Tumors (111) Odds Ratio BP in CCLE (917) Gene Fragile Sites
2 20300001 20400001 2p24.1 0 9 3,73 248 – –
4 190900001 191000001 4q35.2 0 14 5,98 190 FRG2 FRA4L, FRA4M
7 159100001 159119220 7q36.3 0 22 10,11 230 – FRA7I
8 146200001 146300001 8q24.3 0 21 9,56 238 C8orf33* FRA8D
9 141000001 141100001 9q34.3 1 48 14,48 321 CACNA1B* FRA9N
13 115100001 115106996 13q34 3 40 3,19 210 – FRA13I
16 85000001 85100001 16q24.1 0 8 3,30 244 KIAA0513*, ZDHHC7 FRA16J
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heterozygosity or homozygous deletion) and looked for
the relevance of those regions in our dataset concerning
the occurrence of breakpoints. Fragile site FRA16D
(16q23.2) is within a region of frequent loss-
of-heterozygosity in breast and prostate cancers. Inter-
estingly, we found 64 breakpoints in 13 tumor samples
(11.7%) for this fragile site, whereof 61 were found in
nine breast cancer samples (18.75% of all breast cancer
samples). Another frequently altered chromosomal re-
gion is located on chromosome 9 (21,900,001) where the
tumor suppressor p16 (official symbol CDKN2A) is
present. In the corresponding bins, 104 cancer cell lines
had a breakpoint (11.34%) and eight tumor samples
(7.2%). Interestingly, this region is part of the fragile site
FRA9A. In this CFS 56 tumor samples (50.5%) had at
least one breakpoint.
The most commonly known unstable CFS region is
FRA3B [37]. In this CFS, spanning over 43 bins, 148
breakpoints were detected in 26 cancer samples (23.4%).
It is also noteworthy that 23 out of the 26 cancer sam-
ples had a breakpoint in the region of the gene FHIT
lying inside of FRA3B. In line with this, 243 cancer cell
lines have breakpoints in FRA3B and 223 of those have
breakpoints in the 16 bins containing FHIT.
Discussion
In this study, we examined the theory that genome
reorganization during tumorigenesis is not a random
process but rather a directed process, involving defined
DNA regions. Therefore, we have reanalyzed 1.048 DNA
SNP arrays from different cancer entities and
non-malignant samples. We found an increase of DNA
breakpoint regions in tumor samples compared to
NMCE. Interestingly, several breakpoint regions were
common in several tumor specimen (up to 43%) where
as other regions seemed to be more restricted to a spe-
cific tumor entity. Surprisingly, breakpoint regions be-
tween PDCA and PDCA derived cell lines differ
considerably. On the one hand, Kalinina and colleagues
established a pancreatic cancer cell line from a primary
tumor. Kalinina and colleagues also observed a similar
CNV pattern between tumor and cell line after passa-
ging the cell line 15–20 times, as well as a considerable
number of similar large chromosomal alterations [38].
On the other hand, Burdall and colleagues stated that
“Cell lines are prone to genotypic and phenotypic drift
during their continual culture. This is particularly com-
mon in the more frequently used cell lines, especially
those that have been deposited in cell banks for many
years [39].” This might be applicable for the used cell
lines in our approach, e.g. Capan 1 and 2 were estab-
lished 1974 and 1975, respectively [40, 41].
It is well known that cancers develop from stem lines
in a stepwise process and are characterized by
chromosomal aberrations and chromosomal instability
[42, 43]. The Mitelman Database of Chromosome Aber-
rations and Gene Fusions in Cancer currently lists
69,134 human cancers with individual clonal karyotypes
[44]. In 2012, Standfuß et al found a stepwise increase in
genome reorganization in a mouse breast cancer model.
The number of genomic changes increased from
non-malignant, to hyperplastic and to tumor samples of
mammary glands [9]. Further, an analysis of 2.737 tumor
samples from 8 different tumor entities (including breast
cancers) showed that tumor entity-specific breakpoints
could be found for all examined tumor entities. The
breakpoint regions were equally distributed over all en-
tities [45]. Further, colocalization assessment identified
20,077 CNV-affecting genes and 169 of these being
known tumor-related genes. In another study, Berou-
khim et al looked for somatic CNVs in 3.131 cancer spe-
cimen and found 158 regions of focal somatic CNVs of
which only 36 can be explained by the presence of
known cancer target genes located within this region like
FHIT and p16 [8]. Meaburn and Misteli also identified
several genes specifically repositioned during tumorigen-
esis. The alterations of the spatial positioning were unre-
lated to gene activity [15]. In our study, genes were
located in eight of the top-15 and four of the top-7
CCLE breakpoint regions. Eight of these genes are linked
to cancer, but none are well characterized oncogenes or
tumor suppressor genes. Interestingly, only C8orf33 and
NBEA seemed to have tumor suppressor functions [46,
47]. The other six genes are associated with tumor pro-
gression. IBSP, MEPE, RELN and THSD7A are associated
with migration, invasion, infiltration and angiogenesis
[48–51]; CACNA1B and KIAA0513 are associated with
cell proliferation and apoptosis. CACNA1B overexpres-
sion is associated with an unfavorable prognosis in
non-small cellular lung cancer [52] and altered expres-
sion of KIAA0513, due to an aberrant methylation pat-
tern, correlated with non-survivors in Neuroblastoma
[53].
As early as 1984, several scientists postulated an asso-
ciation between human fragile sites and cancer break-
points [25, 26, 54]. CFSs in cancer were considered as
regions of chromosomal instability and their associated
genes are frequently deleted or rearranged in cancer cells
[55]. Since we found a strong correlation of our top
breakpoint regions with fragile sites, we were also inter-
ested to look for breakpoints in specific CFSs described
in literature. Finnis and colleagues found out that the
CFS FRA16D (16q23.2) is located within regions of fre-
quent loss-of-heterozygosity in breast and prostate can-
cers [56]. Here we found a breakpoint almost specific for
breast cancer, since 61 from 64 breakpoints stem from
breast cancer samples. 1986 Smeets and colleagues de-
scribed FRA3B as the most unstable CFS region within
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chromosomal band 3p14.2 [37]. This chromosomal region
is a hot-spot for deletions and other alterations in a variety
of different cancers. FHIT, a large tumor suppressor gene
spanning over approximately 35% of this fragile site, is also
harbored in this region [57]. While 26 tumors and 243
cancer cell lines have a breakpoint in FR3B, the majority
of these breakpoints, namely 23 and 223, lay in the FHIT
gene. Thus, it is not surprising that estimates designate
FHIT as the most frequently altered gene in cancer [58].
Inside the CFS, FRA9A the p16 gene is located. Cox and
Colleagues found in their “survey of homozygous dele-
tions in human cancer genomes” that p16 was the most
frequent target of homozygous deletions (24.6%) [59]. Fur-
ther, they argued that genetic rearrangement in this region
might signify less negative selection compared to other re-
gions because p16 is located adjacent to one of the largest
gene-poor regions of the human genome. When looking
at the direct adjacent bins of p16, it stands out that the
area of and around p16 is the area of FRA9A where most
of the breakpoints occur. This indicates that those break-
points occurring in this CFS might play a role for tumor
development, instead of being a random side effect of gen-
omic instability.
However, genome rearrangements are not restricted to
cancer cells. Rather, they are also present in adaptive
processes, such as response to selective pressures from
the environment and are associated with various diseases
[60–62].
Conclusion
In this study, we found that genome reorganization is
more enhanced in tumor samples compared to the
non-malignant controls and that some genome regions
exist that are prone to rearrangements. We identified re-
gions which may play an important role in the tumori-
genesis of specific tumor entities and others that occur
commonly during tumorigenesis.
For further investigations, genomic profiles could be
linked to clinical data in order to produce additional
prognostic markers for clinical outcome.
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